The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors.
John F. Deeken
Research Funding - GlaxoSmithKline
Hongkun Wang
Research Funding - GlaxoSmithKline
John Marshall
Research Funding - GlaxoSmithKline
Deepa Suresh Subramaniam
Research Funding - GlaxoSmithKline
Jimmy J. Hwang
Research Funding - GlaxoSmithKline
Aiwu Ruth He
Research Funding - GlaxoSmithKline
Corinne Ramos
Employment or Leadership Position - Theranostics Health
Stock Ownership - Theranostics Health
Rosemarie A. Hardesty
No relevant relationships to disclose
Kenneth Steadman
No relevant relationships to disclose
Louis M. Weiner
No relevant relationships to disclose
Michael J. Pishvaian
Research Funding - GlaxoSmithKline